Venous thromboembolism in adults: diagnosis, anticoagulation and duration of treatment

Clinical scope and immediate priorities

Venous thromboembolism includes deep-vein thrombosis and pulmonary embolism and ranges from incidental distal thrombosis to obstructive shock. Good care combines rapid recognition of unstable PE with disciplined use of pre-test probability in stable patients, followed by anticoagulation that is matched to bleeding risk, cancer, pregnancy, renal function and interacting medicines. Haematological abnormalities may represent primary disease, systemic illness, treatment toxicity or laboratory artefact. The urgency depends on symptoms, severity, trend and associated bleeding, thrombosis, infection or organ dysfunction. A blood count should be interpreted with the film, clinical context and relevant biochemical or coagulation studies rather than in isolation.

Recognition and differential diagnosis

Unilateral leg swelling or pain raises suspicion for DVT, while acute dyspnoea, pleuritic pain, tachycardia, haemoptysis or syncope can occur with PE. Symptoms are nonspecific, so use a validated clinical probability approach rather than gestalt alone. Hypotension, severe hypoxaemia, syncope with right-heart strain or rising lactate suggests high-risk PE requiring immediate escalation. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

In low or intermediate probability patients, a high-sensitivity D-dimer can safely avoid imaging when negative, with age-adjusted thresholds supported in many pathways. Compression ultrasound is standard for suspected proximal DVT and CT pulmonary angiography is common for PE; ventilation-perfusion imaging remains useful when CTPA is unsuitable. Assess renal function, haemoglobin, platelets, pregnancy status where relevant and bleeding risk before anticoagulation. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Direct oral anticoagulants are first-line for many stable non-pregnant adults, but LMWH or other strategies may be preferred in pregnancy, severe renal impairment, selected cancers, antiphospholipid syndrome or major interacting therapy. Treatment duration depends on whether the event was provoked by a transient factor, persistent risk, active cancer or unprovoked, and should be revisited rather than defaulting to an arbitrary fixed course. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Haemodynamic instability from PE requires immediate specialist/resuscitation care and consideration of systemic thrombolysis, catheter intervention or surgical embolectomy according to contraindications and local capability. Suspected phlegmasia, limb threat or recurrent thrombosis despite therapeutic anticoagulation also requires urgent specialist review. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. Review adherence, bleeding, renal function and the continuing indication for anticoagulation. Persistent dyspnoea after PE should prompt assessment for post-PE syndrome or chronic thromboembolic pulmonary hypertension rather than reassurance alone.

Common pitfalls and safety checks

Do not order D-dimer indiscriminately in patients with a high pre-test probability who require imaging. Do not assume every VTE requires lifelong anticoagulation or, conversely, that three months is invariably sufficient. Check pregnancy, renal function and interacting medicines before selecting an anticoagulant. Persistent breathlessness after PE deserves clinical reassessment. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Implementation across settings should preserve the trend in blood counts and coagulation results, not merely the latest value. Transfusion, anticoagulation and cytotoxic therapies create safety issues during handover, so document component requirements, antibody history, medicine indication and planned monitoring. Laboratory medicine, transfusion services and pharmacy are important clinical partners. When specialist testing is pending, provide clear thresholds for urgent reassessment rather than waiting passively for an outpatient result in a patient whose cytopenia, bleeding or thrombosis risk is changing.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.